Software as treatments

recent news:Boehringer Ingelheim and Click Therapeutics to Develop and Commercialize a Digital Therapeutic for Schizophrenia in a $500M+ Collaboration Read more

Our Mission

Deliver safe and effective digital treatments to patients in need

We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments.

Developing Software
As Treatments

We are a regulated Software as a Medical Device (SaMD)-focused biotechnology company that develops our applications as medical treatments in accordance with all relevant FDA, ISO and IEC standards.

01
Develop
We develop prescription software applications as medical devices that work independently or in conjunction with pharmacotherapies to treat disease.
02
Validate
We clinically validate these applications through rigorous randomized, controlled trials to demonstrate safety and efficacy.
03
Register
We seek FDA clearance for our apps as class II medical devices with independent therapeutic treatment claims or as adjuncts to existing therapy.
04
Commercialize
Physicians prescribe our apps and payers reimburse for them, while we generate and apply real world evidence to continuously personalize and improve the applications.

Leadership

David B. Klein
Chief Executive Officer
Han Chiu
Chief Technology Officer
Ross Muken
Chief Financial Officer
Austin C. Speier
Chief Strategy Officer
Shaheen Lakhan, MD, PhD, FAAN
Senior Vice President, Research & Development
Heather Knigin
Senior Vice President, People
view whole team

In The News

  • PressDecember 01, 2020
    Click Therapeutics Secures $30M in Growth Capital from K2 HealthVentures to Expand Operations
    read more
  • PressNovember 19, 2020
    Click Therapeutics Announces that Solera Health will Provide Clinically Validated Smoking-Cessation Program Clickotine® to Blue Shield of California Members
    read more
  • PressSeptember 11, 2020
    Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
    read more
  • PressMay 11, 2020
    Click Therapeutics Announces Participation in Upcoming Investor Conferences in May and June
    read more
  • PressApril 23, 2020
    Click Therapeutics Launches New Brand Identity and Redesigned Website
    read more
  • PressFebruary 24, 2020
    Click Therapeutics to Present at the Cowen and Company 40th Annual Healthcare Conference
    read more
  • PressFebruary 11, 2020
    Click Therapeutics Announces Appointment of Top Healthcare Executives Muzammil Mansuri and Jeffrey Berkowitz as Senior Strategic Advisors and Formation of Payer Advisory Board
    read more
  • PressOctober 16, 2019
    Click Therapeutics, Inc. Honored by Goldman Sachs for Entrepreneurship
    read more
  • PressSeptember 04, 2019
    Click Therapeutics Announces Appointment of Top Ranked Healthcare Research Analyst Ross J. Muken as Chief Financial Officer
    read more
  • PressJanuary 03, 2019
    Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder
    read more
  • PressOctober 02, 2018
    Click Therapeutics Expands Executive Team with Chief Medical Officer and Chief Strategy Officer
    read more
  • PressJuly 23, 2018
    Sanofi Ventures Leads $17 Million Financing of Click Therapeutics
    read more
  • PressJune 06, 2018
    Click Therapeutics Announces Multiple Publications Supporting Its Digital Therapeutic for Major Depressive Disorder; Seeking FDA Clearance
    read more
  • PressMay 18, 2018
    Click Therapeutics Awarded National Institutes of Health (NIH) Grant for Clickotine® Digital Therapeutic Study
    read more
  • PressFebruary 14, 2018
    Click Therapeutics Announces the Release of the Click Affective Pictures Set (CAPS) to Researchers Globally
    read more
  • PressApril 25, 2017
    Click Therapeutics Announces Multiple Publications of Clinical Data Supporting Digital Therapeutics™ Programs for Smoking Cessation and Major Depressive Disorder
    read more
  • PressMarch 20, 2017
    Click Therapeutics Presents Data on Increased Efficacy of a Digital Therapeutics™ Program for Smoking Cessation at Six-Month Mark of Clinical Trial
    read more
  • PressSeptember 21, 2016
    Click Therapeutics™ Reports Preliminary Results of a 416-Participant Clinical Study Demonstrating Exceptional Engagement and Efficacy of Clickotine®, a Patent-Pending Digital Therapeutics™ Program for Smoking Cessation
    read more
  • PressApril 20, 2016
    Magellan Health and Click Therapeutics Launch Fully Digital, Integrated and Comprehensive Smoking Cessation Program
    read more

Our Collaborators

Contact us

Email us

Our office

80 White Street
New York, NY 10013